Efficacy and safety analysis of eltrombopag and recombinant human thrombopoietin combined with immunosuppressive therapy for severe aplastic anemia
10.3760/cma.j.issn.0253-2727.2021.12.010
- VernacularTitle:艾曲泊帕、重组人血小板生成素联合标准免疫抑制治疗重型再生障碍性贫血16例疗效及安全性分析
- Author:
Fangfang YUAN
1
;
Qinglan ZHANG
;
Li’na ZHANG
;
Yuanyuan XIONG
;
Mengjuan LI
;
Hu ZHOU
;
Xudong WEI
;
Xinjian LIU
;
Yongping SONG
Author Information
1. 郑州大学附属肿瘤医院，河南省肿瘤医院，河南省血液病研究所 450008
- Keywords:
Anemia, aplastic;
Eltrombopag;
Recombinant human thrombopoietin;
Immunosuppressive therapy
- From:
Chinese Journal of Hematology
2021;42(12):1021-1024
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the efficacy and safety of combination therapy of eltrombopag, recombinant human thrombopoietin (rhTPO) , and standard immunosuppressive therapy (IST) for severe aplastic anemia (SAA) .Methods:A total of 16 cases with SAA treated with IST combined with eltrombopag and rhTPO were retrospectively analyzed.Results:At 3 months, the total response rate was 81.3%, and the complete hematological response rate was 37.5%. At 6 months, the total response rate was 87.5%, and the complete hematological response rate was 50.0%. The median time of platelet transfusion independence was 35 (16-78) days, the median time of red blood cell transfusion independence was 47.5 (15-105) days, the median platelet transfusion was 5.5 (3-20) U, and the median red blood cell transfusion was 6.5 (2-16) U.Conclusion:The combination of eltrombopag and rhTPO can improve the hematological response rate of IST for SAA and the quality of hematological remission with minimal toxic effects.
